Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

InterCure stock

INCR.TA
IL0011063760
A1CZA8

Price

592.00
Today +/-
+0.89
Today %
+0.56 %

InterCure stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the InterCure stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the InterCure stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the InterCure stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze InterCure's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

InterCure Stock Price History

DateInterCure Price
2/13/2025592.00 undefined
2/12/2025588.70 undefined
2/11/2025593.30 undefined
2/10/2025613.60 undefined
2/9/2025601.20 undefined
2/6/2025620.00 undefined
2/5/2025629.30 undefined
2/4/2025597.10 undefined
2/3/2025571.30 undefined
2/2/2025590.00 undefined
1/30/2025585.00 undefined
1/29/2025603.00 undefined
1/28/2025618.20 undefined
1/27/2025619.00 undefined
1/26/2025621.00 undefined
1/23/2025615.00 undefined
1/22/2025615.00 undefined
1/21/2025615.00 undefined
1/20/2025617.50 undefined
1/19/2025626.00 undefined

InterCure Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into InterCure, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by InterCure from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects InterCure’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of InterCure. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into InterCure’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing InterCure’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on InterCure’s growth potential.

InterCure Revenue, EBIT and net profit per share

DateInterCure RevenueInterCure EBITInterCure Net Income
2026e574 M undefined93.5 M undefined80.33 M undefined
2025e404.94 M undefined52.64 M undefined27.9 M undefined
2024e290.7 M undefined12.9 M undefined-1.92 M undefined
2023355.55 M undefined34.29 M undefined-61.96 M undefined
2022388.68 M undefined63.41 M undefined44.82 M undefined
2021219.68 M undefined39.5 M undefined4.69 M undefined
202065.04 M undefined-39.99 M undefined-37.23 M undefined
20198.93 M undefined-3.08 M undefined-5.89 M undefined
20180 undefined-10.62 M undefined-12.8 M undefined
20170 undefined-4.18 M undefined-5.52 M undefined
20160 undefined1.14 M undefined251,000 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20138.54 M undefined-2 M undefined-6.84 M undefined
20128.73 M undefined-2.24 M undefined44.76 M undefined
201111.33 M undefined-1.68 M undefined-6.39 M undefined
201013.91 M undefined-5.26 M undefined-13.21 M undefined
200916.72 M undefined-11.72 M undefined-17.24 M undefined
200824.08 M undefined-24.25 M undefined-21.79 M undefined
200736.59 M undefined-21.33 M undefined-28.99 M undefined
200627.09 M undefined-12.03 M undefined-12.88 M undefined
200518.96 M undefined-9.9 M undefined-9.6 M undefined

InterCure Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
182736241613118800000865219388355290404574
-50.0033.33-33.33-33.33-18.75-15.38-27.27-------712.50236.9277.17-8.51-18.3139.3142.08
66.6766.6775.0066.6768.7576.9272.7375.0075.00-----12.5046.1543.3840.7230.4237.2426.7318.82
1218271611108663000013095158108000
-9-12-28-21-17-13-644-6000-5-12-5-37444-61-12780
-33.33133.33-25.00-19.05-23.53-53.85-833.33-113.64----140.00-58.33640.00-110.811,000.00-238.64-98.36-2,800.00196.30
00000002.685.770012.916.7817.9623.326.1546.9245.3545.57000
----------------------
Details

Keystats

ⓘ

Revenue and Growth

The InterCure Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the InterCure is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200520062007200820092010201120122013201420152016201720182019202020212022
                                   
7.358.442.411.572.811.211.212.533.881.702.892.573.6627.5238.26196.55232.79
1.981.952.732.512.681.681.060.280.440.2800.020.0408.916.1550.65134.29
00000000.040.1600001.30000
0.40.450.842.421.61.110.290.851.05000005.7922.262.31126.5
00000.280.080.080.10.10000000.0426.6513.91
9.7310.845.9716.57.374.082.6313.85.631.9802.922.614.9642.2176.65336.16507.49
0.470.510.821.341.060.50.240.150.110.1200.0100.0932.1553.4786.51103.13
0.210.080.110.100.050.05000021.7722.5430.8839.913.142.5742.57
0000000000000001.2514.2624.84
0000000540400000000000
00000000000000167.97190.1268.29284.18
0.030.0200000000000002.93.0220.64
0.710.610.931.441.060.550.290.690.510.12021.7722.5430.96240.03250.87374.65475.35
10.4411.4146.917.948.434.632.9214.496.142.1024.6925.1535.92282.23327.52710.81982.85
                                   
0.210.220.250.260.230.210.230000142.34153.8162.3403.4452.26623.57632.03
87.7994.03125.31116.71104.1496.9107.96129.03121.43000000000
-86.12-99-120.78-134.82-139.63-142.18-162.86-119.22-117.53-123.50-120.91-132.09-142.64-147.43-177.75-175.54-130.72
-0.12-0.120-1.372.92.692.9100000000000
000000000000000000
1.76-4.874.78-19.22-32.36-42.38-51.769.813.9-123.5021.4321.7219.66255.97274.51448.03501.3
8.429.2911.597.057.6310.6414.042.21.271.370.30.350.333.484.9418.62105.52126.07
00000000.280.26000001.943.4303.86
00000.40.020.110.840.670.6800.780.0201.915.2815.7850.42
0000036.0440.341.3100.3202.133.0812.7813.631.31.721.09
000000000000000.211.2570.56131.28
8.429.2911.597.058.0346.754.494.632.22.370.33.263.4316.2622.6329.88193.58312.72
05.4930.2128.2230.810000000003.214.1333.32122.79
000000000000000000
0.251.490.331.911.960.310.20.050.04000000.190.160.221.03
0.256.9830.5430.1332.770.310.20.050.04000003.44.2833.55123.81
8.6716.2742.1337.1840.847.0154.694.682.242.370.33.263.4316.2626.0334.16227.13436.53
10.4311.446.9117.968.444.632.9314.496.14-121.130.324.6925.1535.92282308.67675.16937.83
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of InterCure provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand InterCure's financial health and stability.

Assets

InterCure's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that InterCure must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of InterCure after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into InterCure's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200520062007200820092010201120122013201420152016201720182019202020212022
-9-12-28-21-17-13-644-6-3-10-5-12-2-36743
0000000000000003711
000000000000000000
200-41110-1000002-4-13-10
016-4274-46410-1410-1144286
0000200000000000517
0000000000000000117
-6-10-22-29-12-30-1-3-1-1-10-1-1173051
00000000000000-28-20-14-19
000-1000000-7-10-2-7-26-22-65-142
000-1000010-7-10-2-72-1-51-122
000000000000000000
-1624030010002080-1365137
1452520002001182166381370
121156131040011113106325197120
00700100000000-20-5-17
000000000000000000
5133-31-8002-202001231015836
-7.11-10.91-22.57-30.8-12.41-3.35-0.82-1.92-3.71-1.72-1.45-1.12-0.97-1.58-39.71-13.0416.1131.53
000000000000000000

InterCure stock margins

The InterCure margin analysis displays the gross margin, EBIT margin, as well as the profit margin of InterCure. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for InterCure.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the InterCure's sales revenue. A higher gross margin percentage indicates that the InterCure retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the InterCure's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the InterCure's total revenue generated. When comparing the revenue margin year over year, investors can gauge the InterCure's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the InterCure. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the InterCure's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

InterCure Margin History

InterCure Gross marginInterCure Profit marginInterCure EBIT marginInterCure Profit margin
2026e30.47 %16.29 %14 %
2025e30.47 %13 %6.89 %
2024e30.47 %4.44 %-0.66 %
202330.47 %9.64 %-17.43 %
202240.9 %16.31 %11.53 %
202143.7 %17.98 %2.14 %
202046.72 %-61.49 %-57.25 %
201916.47 %-34.55 %-66.02 %
201830.47 %0 %0 %
201730.47 %0 %0 %
201630.47 %0 %0 %
201530.47 %0 %0 %
201430.47 %0 %0 %
201377.63 %-23.42 %-80.09 %
201276.4 %-25.66 %512.71 %
201176.08 %-14.83 %-56.4 %
201076.35 %-37.81 %-94.97 %
200968.48 %-70.1 %-103.11 %
200870.43 %-100.71 %-90.49 %
200775.35 %-58.29 %-79.23 %
200669.51 %-44.41 %-47.55 %
200564.72 %-52.22 %-50.63 %

InterCure Stock Sales Revenue, EBIT, Earnings per Share

The InterCure earnings per share therefore indicates how much revenue InterCure has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue InterCure earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates InterCure's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of InterCure’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating InterCure's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

InterCure Revenue, EBIT and net profit per share

DateInterCure Sales per ShareInterCure EBIT per shareInterCure Earnings per Share
2026e12.17 undefined0 undefined1.7 undefined
2025e8.59 undefined0 undefined0.59 undefined
2024e6.16 undefined0 undefined-0.04 undefined
20237.8 undefined0.75 undefined-1.36 undefined
20228.57 undefined1.4 undefined0.99 undefined
20214.68 undefined0.84 undefined0.1 undefined
20202.49 undefined-1.53 undefined-1.42 undefined
20190.38 undefined-0.13 undefined-0.25 undefined
20180 undefined-0.59 undefined-0.71 undefined
20170 undefined-0.25 undefined-0.33 undefined
20160 undefined0.09 undefined0.02 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20131.48 undefined-0.35 undefined-1.19 undefined
20123.26 undefined-0.84 undefined16.7 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined

InterCure business model

InterCure Ltd. is a global company in the medical technology industry that focuses on the development, production, and distribution of innovative solutions for the diagnosis and treatment of chronic diseases. The company was founded in Israel in 2000 and is headquartered in Lod. InterCure is one of the most popular companies on Eulerpool.com.

InterCure SWOT Analysis

Strengths

InterCure Ltd has a strong market presence and brand recognition in the healthcare industry.

The company is backed by a highly skilled and experienced management team.

InterCure has a diverse product portfolio, catering to different segments of the healthcare market.

Weaknesses

InterCure faces stiff competition from other established players in the market.

The company's reliance on a few key suppliers puts it at risk of supply chain disruptions.

InterCure's geographic presence is limited to a few regions, hindering its global expansion opportunities.

Opportunities

InterCure can leverage advancements in technology to develop innovative healthcare solutions.

The growing demand for healthcare services presents an opportunity for InterCure to expand its customer base and market share.

Strategic partnerships and collaborations can help InterCure penetrate new markets and reach a wider audience.

Threats

InterCure faces regulatory uncertainties, which could impact its product development and commercialization processes.

Economic downturns and fluctuations in healthcare spending pose a threat to InterCure's financial performance.

Competitive pricing and cost pressures in the healthcare industry can affect InterCure's profitability.

InterCure Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

InterCure Revenue by Segment

Segmente20232022
Reportable segments [member]355.55 M NIS388.68 M NIS
Cannabis Segment-388.68 M NIS
Cannabis segment [member]355.55 M NIS-
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

InterCure Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

InterCure historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

InterCure shares outstanding

The number of shares was InterCure in 2024 — This indicates how many shares 45.573 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue InterCure earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates InterCure's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of InterCure’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating InterCure's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

InterCure stock splits

In InterCure's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for InterCure.

InterCure latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20230.08 0.11  (28.68 %)2023 Q2
3/31/20230.04 0.01  (-87.75 %)2023 Q1
12/31/20220.18 0.19  (2.58 %)2022 Q4
9/30/20220.26 0.16  (-37.25 %)2022 Q3
3/31/20220.18 0.36  (96.08 %)2022 Q1
12/31/20210.14 -0.06  (-142.02 %)2021 Q4
9/30/20210.15 -0.03  (-119.61 %)2021 Q3
6/30/20210.14 0.12  (-15.97 %)2021 Q2
1

InterCure shareholders

%
Name
Stocks
Change
Date
25.79447 % Rabinovitch (Alexander)12,164,670195,4104/1/2024
9.12407 % Fegel (Yael)4,302,912-34,4514/1/2024
5.51228 % ETF Managers Group, LLC2,599,5901,788,3074/1/2024
4.00691 % Ibex Investors LLC1,889,65806/30/2024
2.18474 % Barak (Ehud)1,030,3251,030,3254/1/2024
0.97492 % Tidal Investments LLC459,772134,0316/30/2024
0.66318 % Cohen (Amos)312,757312,7574/1/2024
0.61816 % Levy (Rami)291,523291,5234/1/2024
0.45059 % HOOPP Investment Management212,50006/30/2024
0.22777 % AdvisorShares Investments, LLC107,414107,4146/30/2024
1
2
3
4
...
5

Most common questions regarding InterCure

What values and corporate philosophy does InterCure represent?

InterCure Ltd represents a strong commitment to promoting wellness and improving quality of life. The company values include innovation, integrity, and excellence. InterCure focuses on developing and commercializing therapeutic solutions that address unmet medical needs, particularly in the fields of respiratory disease and wellness. The corporate philosophy of InterCure revolves around advancing healthcare through cutting-edge technologies and research. With a dedicated team, InterCure aims to revolutionize the way illnesses are managed and to provide accessible treatments for better health outcomes. interCure Ltd is driven by its mission to enhance well-being and empower individuals to live healthier, more fulfilling lives.

In which countries and regions is InterCure primarily present?

InterCure Ltd is primarily present in Israel, the United States, Canada, and Germany.

What significant milestones has the company InterCure achieved?

InterCure Ltd has achieved several significant milestones since its establishment. The company successfully developed and launched the innovative RESPeRATE device, a non-drug, FDA-cleared solution for hypertension. Additionally, InterCure Ltd has expanded its global presence, establishing partnerships and distribution channels in various markets. The company continues to enhance its product portfolio, offering advanced technologies and solutions to address various medical conditions. InterCure Ltd has also experienced notable financial growth and recognition, attracting investments and receiving prestigious awards for its advancements in healthcare. Overall, the company's milestones highlight its commitment to revolutionizing medical treatments and improving patients' well-being.

What is the history and background of the company InterCure?

InterCure Ltd, a leading Israeli medical cannabis company, was founded in 2011. With a focus on improving patients' quality of life, InterCure is dedicated to research, development, production, and distribution of medical cannabis products. The company operates under the brand name "Canndoc" and holds a distinctive presence in both domestic and international markets. With a commitment to excellence, InterCure continuously strives to enhance patient care through its state-of-the-art cultivation facilities, advanced research initiatives, and partnerships with renowned international experts. With a rich history of innovation and a commitment to improving global healthcare, InterCure Ltd has established itself as a prominent player in the medical cannabis industry.

Who are the main competitors of InterCure in the market?

The main competitors of InterCure Ltd in the market include established companies such as GW Pharmaceuticals, Tilray Inc., and Canopy Growth Corporation. These companies also operate within the medical cannabis industry and compete with InterCure in terms of product development, market share, and innovation. InterCure aims to differentiate itself by offering unique medical cannabis products and focusing on research and development to provide enhanced solutions for patients. Despite facing competition from various industry players, InterCure Ltd continues to strive for growth and maintain its market position through strategic partnerships and constant advancements in the field.

In which industries is InterCure primarily active?

InterCure Ltd is primarily active in the medical cannabis industry.

What is the business model of InterCure?

InterCure Ltd is a leading company in the healthcare sector. The business model of InterCure revolves around the development and commercialization of innovative medical solutions to improve patient outcomes. With a strong focus on research and development, InterCure aims to provide advanced therapeutic solutions in areas such as respiratory, cardiovascular, and sleep disorders. The company's commitment to excellence and cutting-edge technology enables it to meet the evolving healthcare needs of individuals worldwide. With a customer-centric approach and a dedication to improving quality of life, InterCure Ltd stands out as a prominent player in the healthcare industry.

What is the P/E ratio of InterCure 2025?

The InterCure P/E ratio is 967.

What is the P/S ratio of InterCure 2025?

The InterCure P/S ratio is 66.62.

What is the Quality Investing of InterCure?

The Quality Investing for InterCure is 3/10.

What is the revenue of InterCure 2025?

The expected InterCure revenue is 404.94 M ILS.

How high is the profit of InterCure 2025?

The expected InterCure profit is 27.9 M ILS.

What is the business model of InterCure

InterCure Ltd was founded in 2000 to offer innovative digital health solutions. The company is based in Israel and provides various products and services targeting telemedicine, chronic diseases, and lifestyle management. Telemedicine InterCure offers an award-winning telemedicine platform called "CardioCare". This platform allows doctors to diagnose, treat, and monitor patients with high blood pressure without them having to come to a clinic. The platform includes a wireless blood pressure monitor connected to the patient's "CardioCare" app. By using this technology, the doctor can monitor the patient's blood pressure in real time and adjust the medication accordingly. Chronic diseases InterCure also offers products for managing chronic diseases such as asthma, diabetes, and COPD. The "RespeRate" is a breathing training device designed for patients with respiratory diseases. The device helps regulate breathing rhythm and patterns to improve the quality of breath and reduce symptoms. Lifestyle management Another product offered by InterCure is "Relaxing Moments". This app includes audio and video content for stress management and relaxation. The app was developed in collaboration with leading relaxation and stress reduction experts and includes exercises for breathing, meditation, and mindfulness. InterCure has also partnered with the company "Glucovation" to develop a "Smart Patch" for diabetics. This patch continuously measures blood glucose levels and sends this data to an app on the patient's smartphone. Through these continuous measurements, the patient can adjust medication in real time. Overall, InterCure offers a wide range of products and services aimed at improving patients' health and well-being. By utilizing digital technology, telemedicine, and collaborating with experts in various fields, InterCure supports patients in managing chronic diseases, relaxation, and disease prevention.

What is the InterCure dividend?

InterCure pays a dividend of 0 ILS distributed over payouts per year.

How often does InterCure pay dividends?

The dividend cannot currently be calculated for InterCure or the company does not pay out a dividend.

What is the InterCure ISIN?

The ISIN of InterCure is IL0011063760.

What is the InterCure WKN?

The WKN of InterCure is A1CZA8.

What is the InterCure ticker?

The ticker of InterCure is INCR.TA.

How much dividend does InterCure pay?

Over the past 12 months, InterCure paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, InterCure is expected to pay a dividend of 0 ILS.

What is the dividend yield of InterCure?

The current dividend yield of InterCure is .

When does InterCure pay dividends?

InterCure pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of InterCure?

InterCure paid dividends every year for the past 0 years.

What is the dividend of InterCure?

For the upcoming 12 months, dividends amounting to 0 ILS are expected. This corresponds to a dividend yield of 0 %.

In which sector is InterCure located?

InterCure is assigned to the 'Health' sector.

Wann musste ich die Aktien von InterCure kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of InterCure from 2/15/2025 amounting to 0 ILS, you needed to have the stock in your portfolio before the ex-date on 2/15/2025.

When did InterCure pay the last dividend?

The last dividend was paid out on 2/15/2025.

What was the dividend of InterCure in the year 2024?

In the year 2024, InterCure distributed 0 ILS as dividends.

In which currency does InterCure pay out the dividend?

The dividends of InterCure are distributed in ILS.

All fundamentals about InterCure

Our stock analysis for InterCure Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of InterCure Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.